Updates
PharmEnable appoints Professor Jackie Hunter CBE as Corporate Advisor
We’re delighted to welcome Professor Jackie Hunter CBE as Corporate Advisor to PharmEnable. Jackie’s deep experience in pharma R&D, strategic partnerships and AI-driven innovation will be invaluable as PharmEnable advances its pipeline and collaborations....
Clinical oncology pioneer joins PharmEnable’s board
Exciting news at PharmEnable: we are proud to welcome Dr Ian Collins to our board as a new non-executive director. With three decades of experience in drug discovery and drug development, Ian will support our mission to push the boundaries of what is possible in the...
PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration
PharmEnable Therapeutics and Sosei Heptares Expand Drug Discovery Collaboration The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality...
PharmEnable Closes $7.5M Financing led by MP Healthcare
PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases $7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group....
Complex and structurally diverse: the next generation of small molecules
Small molecule drug discovery programmes often use commercial or proprietary compound libraries: a broad collection of molecules that are built by combining a wide variety of synthetically tractable building blocks. With such an extensive array of combinatorial...
PharmEnable announces multi-target collaboration with Denali Therapeutics in neurodegenerative disease
The strategic collaboration aims to accelerate drug discovery in neurodegenerative disease Joint research programmes against multiple undisclosed targets to be initiated over the next two years PharmEnable to receive an upfront cash payment and potential milestone...
PharmEnable awarded PLG Collaboration Deal of the Year Award
We are delighted that our business development team has been recognised with the prestigious Collaboration Deal of the Year Award by the Pharmaceutical Licensing Group for our shared-risk collaboration with Sosei Heptares, an international biopharmaceutical group. The...
How an AI drug discovery collaboration between Nxera and PharmEnable is accelerating complex science: generating new hit molecules against a difficult GPCR target
Artificial Intelligence (AI) is becoming an increasingly important part of drug discovery – as demonstrated by the significant progress in the ongoing collaboration between Nxera and PharmEnable focused on a challenging peptidergic G protein-coupled receptor (GPCR)...
PharmEnable and LifeArc partner to discover novel oral antiviral drugs to treat coronaviruses
PharmEnable is delighted to announce that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to apply their respective technologies and expertise to discover novel oral antiviral drugs with activity against...
In focus: Unlocking the potential of GPCR targets
GPCR representation, the tertiary structure of bovine rhodopsin within the cell membrane (in grey). Source: Wikimedia Commons PharmEnable has recently partnered with Sosei Heptares to work on a challenging G protein-coupled receptor (GPCR) target for a neurology...